-Histologically documented primary CNS lymphoma or secondary diffuse large B-cell lymphoma
(DLBCL) isolated to the CNS with either:
- Relapsed or refractory disease with at least 1 prior therapy OR
- Ineligible for high dose methotrexate based therapy as determined by the treating
physician, including previously untreated patients.
Note: For patients with history of histologically documented systemic DLBCL with CNS
relapse, biopsy of the CNS lesion is recommended but not required.
- Patients must have evaluable disease. This includes radiographic evidence of
parenchymal disease or leptomeningeal enhancement or thickening, or disease detected
in the CSF.
*Patients with vitreous involvement alone are not eligible.
- ECOG performance status of 0, 1, or 2. Patients with ECOG performance status of 3 are
permitted if their performance status limitations are due to lymphoma in the opinion
of the treating physician.
- Participants must have adequate bone marrow and organ function shown by:
- Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
- Platelets ≥ 75 x 10^9/L and no platelet transfusion within the past 7 days prior
to study registration
- Prothrombin time (PT), partial thromboplastin time (PTT), and international
normalized ratio (INR) < 2 times the upper limit of normal
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times
the upper limit of normal
- Serum bilirubin ≤ 1.5 times the upper limit of normal
- Creatinine clearance > 30 mL/min calculated by the Cockcroft-Gault formula using
actual body weight
- Age ≥ 18 years of age
- Body weight >30 kg
- Evidence of post-menopausal status or negative urinary or serum pregnancy test for
female pre-menopausal patients. Women will be considered post-menopausal if they have
been amenorrheic for 12 months without an alternative medical cause. The following
age-specific requirements apply:
- Women <50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of exogenous hormonal
treatments and if they have luteinizing hormone and follicle-stimulating hormone
levels in the post-menopausal range for the institution or underwent surgical
sterilization (bilateral oophorectomy or hysterectomy).
- Women ≥50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of all exogenous hormonal
treatments, had radiation-induced menopause with last menses >1 year ago, had
chemotherapy-induced menopause with last menses >1 year ago, or underwent
surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or
- Female subjects of childbearing potential must have a negative pregnancy test no more
than 3 days prior to the start of study treatment.
- Able to understand and willing to sign an IRB approved written informed consent
document. A legally authorized representative can consent on behalf of a patient who
is able to understand the purpose and risk of the study but not able to provide a
signature on the ICF and authorization to use PHI due to neurologic deficits (e.g.
motor or language deficits)
- Concurrent use of other approved or investigational antineoplastic agents (with the
exception of corticosteroids)
- Participation in another clinical study with an investigational product during the 4
weeks prior to the first day of study treatment.
- Prior chemotherapy or targeted small molecule therapy (or other therapy for CNS
lymphoma) within 3 weeks prior to the first day of study treatment (or 5 half-lives
(whichever is shorter)), or 2 weeks prior to the first day of study treatment for
*The patient must have recovered to baseline or ≤ grade 1 from prior toxicities of
therapy with the exception of alopecia. Recovery to ≤ grade 2 neuropathy is permitted
- External beam radiation therapy to the CNS within 14 days of the first day of study
- Patient requires more than 8 mg of dexamethasone daily or the equivalent for control
of CNS symptoms at the time of initiation of study therapy.
- History of intracranial hemorrhage or clinically significant stroke within 6 months
prior to enrollment
- Inability to swallow oral medications.
- History of significant gastrointestinal disease that would limit absorption of oral
- Active concurrent malignancy requiring active therapy.
- Prior therapy with a checkpoint inhibitor, including durvalumab.
- Prior therapy with BTK inhibitor.
- Warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists.
Patients must be off warfarin-derivative anticoagulants for at least seven days prior
to starting the study drug. Use of low molecular weight heparin and novel oral
anticoagulants (eg. rivaroxaban, apixaban) is permitted if required.
- Concurrent use of a moderate or strong inhibitor or inducer of the P450 isoenzyme
CYP3A. Participants must be off P450/CYP3A inhibitors and inducers prior to starting
the study drug.
- Requires treatment with proton pump inhibitors (e.g., omeprazole, esomeprazole,
lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving
proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible
for enrollment to this study.
- Use of systemic immunosuppressant therapy, including cyclosporine A, tacrolimus,
sirolimus, and other such medications, or chronic administration of > 10 mg/day of
prednisone or the equivalent. This does not refer to patients on corticosteroids for
CNS lymphoma symptoms. Participants must be off of immunosuppressant therapy (with the
exception of steroids) for at least 14 days prior to the first day of study treatment.
The items listed below are exceptions to this criterion:
- Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra
- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of
prednisone or its equivalent
- Steroids as premedication for hypersensitivity reactions (e.g., CT scan
- Receipt of live attenuated vaccine within 30 days prior to the first day of study
treatment. Note: Patients, if enrolled, should not receive live vaccine while
receiving IP and up to 30 days after the last day of study treatment.
- Suspicion of or confirmed progressive multifocal leukoencephalopathy
- Active autoimmune disease (including autoimmune hemolytic anemia and immune
thrombocytopenia purpura) requiring systemic treatment within the past two years (i.e.
with the use of disease modifying agents, corticosteroids, or immunosuppressive
drugs). The following are exceptions to this criterion:
- Patients with vitiligo or alopecia
- Patients with hypothyroidism (e.g., due to Hashimoto syndrome) stable on hormone
- Any chronic skin condition that does not require systemic therapy
- Patients without active disease in the last 5 years may be included but only
after consultation with the study physician
- Patients with celiac disease controlled by diet alone
- Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroids
replacement therapy for adrenal or pituitary insufficiency, etc.)
- Significant medical diseases or conditions, as assessed by the investigator, that
would substantially increase the risk to benefit ratio of participating in the study.
This includes, but is not limited to, acute myocardial infarction in the past 6
months, unstable angina, uncontrolled diabetes mellitus, significant active
infections,, severely immunocompromised state, and congestive heart failure, New York
Heart Association Class III-IV.
- Known bleeding diathesis (e.g. von Willebrand's disease), hemophilia, or active
- Known Human immunodeficiency virus (HIV) infection.
- Known active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as
determined by serologic tests and/or PCR.
- History of invasive fungal infection, including invasive aspergillosis, or known
- Major surgery ≤ 28 days prior to starting the trial treatment (or has not recovered
from the side effects of such surgery) or plans to have surgery within 2 weeks of the
first dose of the study drug.
- Prior allogenic stem cell transplant (autologous stem cell transplant is NOT an